Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.52 |
| ▸ | FNTB | P49356 | 6/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8953501 | 0.87 | HDAC2 (0.51) | FNTAFNTBPGGT1BHDAC2LMNA | |
| SCHEMBL8953498 | 0.87 | HDAC2 (0.51) | FNTAFNTBPGGT1BHDAC2LMNA | |
| SCHEMBL18618666 | 0.86 | CYP2C9 (0.54) | FNTAFNTBPGGT1BHDAC2CYP2C9 | |
| SCHEMBL18618664 | 0.85 | HDAC2 (0.62) | FNTAFNTBPGGT1BHDAC2LMNA | |
| SCHEMBL11113309 | 0.85 | FNTA (0.59) | FNTAFNTBPGGT1BLMNAMAPK1 | |
| SCHEMBL23922617 | 0.83 | CYP2C9 (0.47) | FNTAFNTBPGGT1BHDAC2LMNA | |
| SCHEMBL16489771 | 0.82 | SLC6A5 (0.58) | FNTAFNTBPGGT1BHDAC2SLC6A5 | |
| SCHEMBL18618708 | 0.82 | SLC6A5 (0.57) | HDAC2SLC6A5 | |
| SCHEMBL7081466 | 0.81 | FNTA (0.50) | FNTAFNTBPGGT1BHDAC2LMNA | |
| SCHEMBL7081469 | 0.81 | FNTA (0.50) | FNTAFNTBPGGT1BHDAC2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | UWM RESEARCH FOUNDATION, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| WO-2017039726-A1 | NOVEL HDAC INHIBITORS AND METHODS OF TREATMENT USING THE SAME | UWM RESEARCH FOUNDATION, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | HDAC4, HDAC2, HDAC8 | FNTA 4294/4885FNTB 3392/4885PGGT1B 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.